04 Apr Impel NeuroPharma Expands Patent Portfolio
The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company’s Precision Olfactory Delivery™ or POD™ technology. Patent number 9,919,117, entitled “NOZZLES FOR NASAL DRUG DELIVERY,” is directed to nozzles used in the POD™ technology to allow drug administration into the deep nasal cavity to improve absorption and consistency. Impel is currently developing treatments for migraine, Parkinson’s disease, agitation in schizophrenia, and Alzheimer’s disease that are intranasally delivered.
“This is an important addition to our growing portfolio of issued patents covering our POD™ technology,” stated Dr. John Hoekman, CSO and Founder of Impel. “Our POD™ devices enable our drug-device combination products to address serious unmet patient needs in central nervous system disorders and improve clinical outcomes.”
Impel NeuroPharma’s POD™ device is designed to deliver drugs to the nasal cavity for improved biodistribution. By delivering therapeutics to the nasal cavity, the POD™ device takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for the development of more effective drugs and expand the range of treatment options available to patients.